InDanio secures funding

InDanio technology provides insight into drug activity

The Ontario Genomics Institute announced today that it has awarded MaRS client InDanio BioScience $100,000 of development funding under its Pre-Commercialization Business Development Fund (see press release here).

InDanio Bioscience has developed a revolutionary approach to drug discovery based on human nuclear receptor gene expression.  Using the InDanio approach, drug developers can quickly confirm which nuclear receptor is targeted and also the main tissues where the drug is active.

Nuclear receptors are common drug targets and having greater insight into the impact of novel drugs on these receptors is of great commercial value.

Related Blogs

 

Peek into the future of medicine at MaRS!
The future of medicine is fast approaching. On November 17 we’ll be holding our third annual MaRS Future of Medicineâ„¢ Conference, featuring an exciting agenda highlighting some of the greatest

Can open innovation close the pharma productivity gap?
Analysis of research and development (R&D) expenditures compared to the number of new molecular entities approved by the Food and Drug Administration (FDA) each year indicates that there is defi

How much does it cost to develop a new drug?
The popular view of drug development is that it is fantastically expensive undertaking.  The most recent cost estimate (according to research published by the Tufts Center for the Study of Drug Deve

Clients wow at BioPartnering
Our life sciences and health care practice took three MaRS clients on the road to Vancouver last month to attend the 2011 BioPartnering North America (BPNA) meeting, the first major life sciences bus

One step closer to better chemo for cancer
Congratulations to MaRS client RNA Diagnostics Inc., winners of the 2010 sanofi pasteur Healthcare and Biotechnology Venture Challenge (HBVC)! Rna Diagnostics’ product target is called RNA Disr

Great risk for great reward: Entrepreneurship in the life sciences
On a scale of 1 to 10, how well do you accept risk? According to Greg Hines, CEO of ArcticDx Inc., you had better be a seven or above if you want to work in a start-up environment. At last Wednesdayâ

Tags: awards & competitions, clients, drug development, indanio bioscience, John McCulloch, life sciences, MaRS, OGI